Alteco Medical

The company’s flagship product, the Alteco LPS Adsorber, has been commercially available since 2007. Clinical use demonstrates reduction in endotoxin and inflammatory markers such as procalcitonin and lactate, reduced vasopressor support requirements, improved hemodynamic stability, and improved SOFA scores in patients with severe sepsis/endotoxemia when standard treatments are insufficient. The device acts as an add-on therapy for extracorporeal blood purification. No large-scale pivotal trial data are referenced; clinical benefits are based on real-world use and published studies indicating positive effects on relevant biomarkers and patient stabilization.